Hi everyone,
I am conducting a longitudinal dMRI study on a cohort of young individuals with suspected mild Traumatic Brain Injury (mTBI), evaluated at two timepoints:
-
Session 1: Acute/subacute symptomatic stage.
-
Session 2: Follow-up at approximately 3 months (recovery stage).
I do not have a dedicated healthy control group, so each participant acts as their own longitudinal control. Using both the automated gbarisano/alps pipeline (fed with QSIPrep outputs) and manual ROI validation, I observe index values ranging from 1.3 to 1.9 across the cohort. The automated and manual measurements correlate tightly.
Since this is a young population, I have a few methodological and interpretive questions:
-
In young healthy individuals, baseline DTI-ALPS values often peak around 1.6–1.8. Are values around 1.3 consistent with acute glymphatic/perivascular disruption in symptomatic youth, while 1.8–1.9 represents spared/unaffected status?
-
Without a normative reference group, what is the best statistical approach to evaluate normalization over the 3-month window? Is modeling ΔALPS against symptom recovery scores sufficient, or should I normalize against a reference tract (e.g., standard MD/FA in the corpus callosum)?
Thanks in advance for sharing your experience and advice.